Some clinical aspects of antiresorptive treatment in patients with bone metastases
https://doi.org/10.25789/YMJ.2025.92.27
Abstract
The review article discusses some aspects of the use of anti-resorptive therapy to preserve bone microarchitecture and reduce the risk of fractures in patients with bone metastases. The authors conclude that there is currently no alternative to ART for the prevention of bone complications and the management of pain.
About the Authors
A. V. Kozlovskaya
ФГБОУ ВО «СГУ им. Питирима Сорокина»
Russian Federation
Russian Federation
A. P. Galin
ФГБОУ ВО «СГУ им. Питирима Сорокина»; ГУ «Коми республиканский онкологический диспансер»
Russian Federation
Russian Federation
References
1. Use of bone-modifying agents (BMAs) for the prevention and treatment of bone tissue pathology in malignant neoplasms / S.G. Bagrova S.G., M.V. Kopp, S.I. Kutukova [et al.] // Malignant Tumors. 2020. Vol. 10. No. 3s2-2. P. 35–44. doi: 10.18027/2224-5057-2020-10-3s2-38.
2. Clinical guidelines of the Ministry of Health of the Russian Federation "Bronchial Malignant Neoplasm. 2022
3. Clinical guidelines of the Ministry of Health of the Russian Federation "Breast Cancer". 2021.
4. Clinical guidelines of the Ministry of Health of the Russian Federation "Prostate Cancer". 2021.
5. Pokul L.V. Opportunities for antiresorptive therapy in patients with bone disorders following antitumor treatment // Difficult Patient. 2012. Vol. 10. No. 5. P. 44-48.
6. Prevention and Treatment of Bone Tissue Pathology in Malignant Neoplasms / S.G. Bagrova, E.M. Basin, K.A. Borzov [et al.] // RUSSCO Practical Guidelines, Part 2. Malignant Tumors. 2023. Vol. 13, No. 3s2, P. 44-59. doi: 10.18027/2224-5057-2023-13-3s2-2-44-59.
7. The role of bone-modifying agents in the prevention of skeletal-related events during combined treatment of malignant neoplasms (literature review) / R.N. Safin, I.R. Safin, R.Sh. Khasanov [et al.] // Volga Region Oncology Bulletin. 2024. Vol. 15. No. 2. P. 87-102. doi: 10.32000/2078-1466-2024-2-87-102.
8. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density / E. Orwoll, C. Teglbjærg, B. Langdahl [et al.] // J Clin Endocrinol Metab. 2012. V.97. P.9. P.3161-3169. doi: 10.1210/jc.2012-1569.
9. Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis / J. Lu, D. Hu, C. Ma [et al.] // Front. Pharmacol. 2022. V.13. P.938447. doi: 10.3389/fphar.2022.938447.
10. Bigi A., Boanini E. Calcium Phosphates as Delivery Systems for Bisphosphonates // J Funct Biomater. 2018. V.9. N.1. P.6. doi: 10.3390/jfb9010006.
11. Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials / H.H. Van Acker, S. Anguille, Y. Willemen [et al.] // Pharmacol Ther. 2016 Feb. N.158. P. 24-40. doi: 10.1016/j.pharmthera.2015.11.008. Epub 2015 Nov 23. PMID: 26617219.
12. Bone health in cancer: ESMO Clinical Practice Guidelines // Ann Oncol. 2020. Dec; 31. V.12. P. 1650-1663. doi: 10.1016/j.an-nonc.2020.07.019.
13. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials / L. Jiang, X. Cui, H. Ma [et al.] // J Orthop Surg Res. 2021. Jun 22. V.16. N.1. P. 400. doi: 10.1186/s13018-021-02554-8.
14. Delayed Denosumab Injections and Fracture Risk Among Patients with Osteoporosis : A Population-Based Cohort Study / H. Lyu, K. Yoshida, S.S. Zhao [et al.] // Ann. Intern Med. 2020. V.173. N.7. P.516-526. doi:10.7326/m20-0882.
15. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study / A.T. Stopeck, A.Lipton, J.-J. Body [et al.] // J Clin Oncol. 2010. Dec 10. V.28. N.35. P. 5132-5139. doi: 10.1200/JCO.2010.29.7101.
16. Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells / Z. Su, M.C.F. Yeung, S. Han [et al.] // Cancer Immunol Res. 2025. May 2. V.13. N.5. P. 646-660. doi: 10.1158/2326-6066.CIR-24-1094.
17. Denosumab versus zoledronic acid for the treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study / K. Fizazi, M. Carducci, M. Smith [et al.] // Lancet. 2011. Mar 5.V. 377. N.9768. P. 813-822. doi: 10.1016/S0140-6736(10)62344-6.
18. Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials / B.G. Wajda, L.E. Ferrie, A.G. Abbott [et al.] // Cancers. 2025. V.17. P. 388. doi: 10.3390/cancers17030388.
19. Denosumab: mechanism of action and clinical outcomes / D.A. Hanley, J.D. Adachi, A. Bell [et al.] // Int J Clin Pract. 2012. V.66. N.12. P.1139-1146. doi: 10.1111/ijcp.12022.
20. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases/ A.L. Himelstein, J.C. Foster, J.L. Khatcheressien [et al.] // JAMA. 2017. Jan 3. V.317. N.1. P. 48-58. doi: 10.1001/jama.2016.19425.
21. Experience With Denosumab (XGEVA®) for prevention of skeletal-related eventsin the 10 years after approval / B. Cadieux, R. Coleman, P. Jafarinasabian [et al.] // Journal of Bone Oncology. 2022. Feb 7. V.33. P. 100416. doi: 10.1016/j.jbo.2022.100416.
22. https://oncology-association.ru/clini-cal-guidelines-update
23. Immune function and diversity of osteoclasts in Normal and pathological conditions / M.B. Madel, L. Ibanez, A. Wakkach [et al.] // Front Immunol. 2019. V.10. P.1408. doi: 10.3389/fim-mu.2019.01408.
24. Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study / C. Brunner, M. Arvandi, C. Marth [et al.] // Journal of Clinical Oncology. 2025. V.43. N.2. P. 180-188. doi: 10.1200/JCO.24.00171.
25. Maraka S., Kennel K. A. Bisphosphonates for the Prevention and Treatment of Osteoporosis // BMJ. 2015. V.351. P.h3783. doi:10.1136/bmj.h3783.
26. Michaelson M.D., Smith M.R. Bisphosphonates for treatment and prevention of bone metastases // J Clin Oncol. 2005. V.23. N.32. P.8219-8224. doi: 10.1200/JCO.2005.02.9579.
27. Miller P.D. Denosumab: Anti-RANKL antibody // Curr Osteoporos Rep. 2009. V.7. P. 18-22. doi: 10.1007/s11914-009-0004-5.
28. Pazianas M., van der Geest S., Miller P. Bisphosphonates and bone quality // Bonekey Rep. 2014. V.3. P.529. doi: 10.1038/bonekey.2014.24.
29. Perry C.M., Figgitt D.P. Zoledronic acid: a review of its use in patients with advanced cancer // Drugs. 2004. V.64. N.11. P. 1197-1211. doi: 10.2165/00003495-200464110-00004.
30. Prideaux M., Findlay D.M., Atkins G.J. Os-teocytes: the master cells in bone remodeling // Curr Opin Pharmacol. 2016. V.28. P.24-30. doi: 10.1016/j.coph.2016.02.003.
31. T. John Martin. Bisphosphonates - mechanisms of action // Australian Prescriber 2000; V. 23. N.6. P.130-132.
32. Thompson K. Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase Endocytosis // Molecular Pharmacology. 2006. V.69. N.5. P. 1624-1632. doi: 10.1124/mol.105.020776.
33. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review / L. Wang, D. Fang, J. Xu et al. // BMC Cancer. 2020. V.20. N.1. P.1059. doi: 10.1186/s12885-020-07568-9.
Review
For citations:
Kozlovskaya A.V., Galin A.P. Some clinical aspects of antiresorptive treatment in patients with bone metastases. Yakut Medical Journal. 2025;(4):126-129. (In Russ.) https://doi.org/10.25789/YMJ.2025.92.27
Views:
25
JATS XML
Email this article 